Axicabtagene ciloleucel

Drug Profile

Axicabtagene ciloleucel

Alternative Names: KTE-C19; KTE-C19 CAR

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Cabaret Biotech
  • Developer Genentech; Kite Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Gene transference; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Acute lymphoblastic leukaemia; Follicular lymphoma; Mantle-cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Non-Hodgkin's lymphoma
  • Phase II Mantle-cell lymphoma
  • Phase I/II Acute lymphoblastic leukaemia
  • Phase I Leukaemia

Most Recent Events

  • 14 Mar 2017 Updated efficacy data from a phase I trial in Non-Hodgkin Lymphoma released by Kite Pharm
  • 28 Feb 2017 Kite Pharma announces intention to submit MAA to the EMA in 2017
  • 28 Feb 2017 Updated efficacy and adverse events data from a phase I/II ZUMA-1 trial in Non-hodgkin lymphoma released by Kite Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top